Clinical trial · Interventional
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule
NCT05281237CI-TRIAL-00107672recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer Stage I | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Lung Cancer Stage II | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Stage I - II Primary Lung Cancer | Lung Neoplasm | PROBABILISTIC | 0.70 |
| Stage II Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Stage I Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AveCure 16 Gauge Flexible Microwave Ablation Probe | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES
- description
- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm. * CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure. * Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology.
- interventionNames
- Device: AveCure 16 Gauge Flexible Microwave Ablation Probe
Primary outcomes (2)
- measure
- Rate of Planned Ablations.
- timeFrame
- Day 1
- description
- Feasibility of performing the procedure as planned in the enrolled patients. At least 9/10 of the planned ablations (90%) can be performed bronchoscopically according to the established protocol.
- measure
- Pathological changes in the tumor tissue.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE. * Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards * Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively * Resection/surgical candidate (lobectomy or greater) * Participants must be at least 22 years old and able to provide consent Exclusion Criteria: * Subjects in whom flexible bronchoscopy is contraindicated * Target nodule \< 1.0 cm * Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor * Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives * Pacemaker, implantable cardioverter, or another electronic implantable device * Patient cannot tolerate bronchoscopy * Patients with coagulopathy * Patients in other therapeutic lung cancer studies * Subject is pregnant or breastfeeding * COVID-19 positive patient at the time of procedure.
References
Publications (1)
- DERIVEDBeattie J, Parrish R, Ayasa L, Aranguren P, Uribe-Buritica FL, Lopez MN, Pineda CM, Cheng G, Senitko M, Abdelghani R, Magge A, Avendano CA, Kheir F, Swenson K, Parikh M, Wilson J, VanderLaan PA, Gangadharan S, Majid A. Safety and feasibility of bronchoscopic microwave ablation technology for peripheral lung cancer: a multi-center, prospective, single-arm study protocol. BMC Surg. 2025 Oct 24;25(1):497. doi: 10.1186/s12893-025-03230-y. PMID 41137055